# US 11,028,141 B2 · Therapeutic for the prevention and/or treatment of weight gain and/or diabetes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,028,141 B2
- Document ID: US11028141B2
- Status: Granted
- Kind: B2
- Application number: 16/348,443
- Filed: 2017-11-09
- Published: 2019-09-05
- Granted: 2021-06-08
- Earliest claimed: 2016-11-09
- Assignees: Baylor College of Medicine
- Applicants: Baylor College of Medicine
- Inventors: Robert Allen Britton; Catherine Tomaro-Duchesneau
- Web page: https://patentgrep.com/patent/US11028141B2

## CPC

- C07K 14/605: Glucagons
- A61K 38/16: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof {(enzyme inhibitors A61K38/005)}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/04: Anorexiants; Antiobesity agents
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Embodiments of the disclosure encompass compositions and methods for the treatment of medical conditions in which increases in GLP-1 are beneficial to an individual. In specific embodiments, the disclosure concerns certain peptides that are capable of inducing GLP-1 production in an individual with a medical condition, such as type II diabetes or obesity. In other cases, an individual is not obese or overweight but is provided the peptide in an effort to reduce weight from fat.

## Claims

### Claim 1

A method of treating a medical condition in an individual having insufficient levels of glucagon-like peptide-1 (GLP-1), comprising the step of administering to the individual a therapeutically effective amount of a peptide comprising MAADIISTIGDLVKWIIDTVNKFKK (SEQ ID NO:1), or a functionally active fragment or derivative thereof; wherein the functionally active fragment comprises at least the amino acids between, and including, positions 3-24 of SEQ ID NO:1; wherein the derivative comprises only conservative amino acid substitutions to SEQ ID NO:1, wherein the medical condition is obesity, type II diabetes, being overweight, Metabolic syndrome, Non-alcoholic fatty liver disease (NAFLD), short bowel syndrome, or a combination thereof.

### Claim 2 (depends on 1)

The method of claim 1, wherein the individual is administered another therapy for the medical condition.

### Claim 3 (depends on 1)

The method of claim 1, further comprising the step of determining the level of GLP-1 in the individual, wherein the therapeutically effective amount depends on the level of GLP-1 in the individual.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide consists of the sequence of SEQ ID NO:1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the peptide consists essentially of the sequence of SEQ ID NO:1.

### Claim 6 (depends on 1)

The method of claim 1, wherein the sequence of the derivative is at least 85, 90, or 99% identical to the sequence in SEQ ID NO: 1.

### Claim 7

A method of treating a medical condition in an individual having insufficient levels of glucagon-like peptide-1 (GLP-1), comprising the step of administering to the individual a therapeutically effective amount of a peptide comprising MAADIISTIGDLVKWIIDTVNKFKK (SEQ ID NO:1), or a derivative thereof; wherein the derivative comprises only conservative amino acid changes to SEQ ID NO: 1 and does not have an alteration in the underlined positions of SEQ ID NO: 1 as follows: MAADIISTIGDLVKWIIDTVNKFKK, wherein the medical condition is obesity, type II diabetes, being overweight, Metabolic syndrome, Non-alcoholic fatty liver disease (NAFLD), short bowel syndrome, or a combination thereof.